Search

Your search keyword '"Poca M"' showing total 165 results
Start Over Author "Poca M" Language english
165 results on '"Poca M"'

3. TGF-β Receptor Inhibitors Target the CD44 high/Id1 high Glioma-Initiating Cell Population in Human Glioblastoma

Author

Anido, Judit, Sáez-Borderías, Andrea, Gonzàlez-Juncà, Alba, Rodón, Laura, Folch, Gerard, Carmona, Maria A., Prieto-Sánchez, Rosa M., Barba, Ignasi, Martínez-Sáez, Elena, Prudkin, Ludmila, Cuartas, Isabel, Raventós, Carolina, Martínez-Ricarte, Francisco, Poca, M. Antonia, García-Dorado, David, Lahn, Michael M., Yingling, Jonathan M., Rodón, Jordi, Sahuquillo, Juan, Baselga, José, and Seoane, Joan

Published
2010
Full Text
View/download PDF

9. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research

Author

Maas, A, Menon, D, Adelson, P, Andelic, N, Bell, M, Belli, A, Bragge, P, Brazinova, A, Büki, A, Chesnut, R, CITERIO, GIUSEPPE, Coburn, M, Cooper, D, Crowder, A, Czeiter, E, Czosnyka, M, Diaz arrastia, R, Dreier, J, Duhaime, A, Ercole, A, Van Essen, T, Feigin, V, Gao, G, Giacino, J, Gonzalez lara, L, Gruen, R, Gupta, D, Hartings, J, Hill, S, Jiang, J, Ketharanathan, N, Kompanje, E, Lanyon, L, Laureys, S, Lecky, F, Levin, H, Lingsma, H, Maegele, M, Majdan, M, Manley, G, Marsteller, J, Mascia, L, Mcfadyen, C, Mondello, S, Newcombe, V, Palotie, A, Parizel, P, Peul, W, Piercy, J, Polinder, S, Puybasset, L, Rasmussen, T, Rossaint, R, Smielewski, P, Söderberg, J, Stanworth, S, Stein, M, Von Steinbüchel, N, Stewart, W, Steyerberg, E, Stocchetti, N, Synnot, A, Te Ao, B, Tenovuo, O, Theadom, A, Tibboel, D, Videtta, W, Wang, K, Williams, W, Wilson, L, Yaffe, K, Adams, H, Agnoletti, V, Allanson, J, Amrein, K, Andaluz, N, Anke, A, Antoni, A, Van As, A, Audibert, G, Azaševac, A, Azouvi, P, Azzolini, M, Baciu, C, Badenes, R, Barlow, K, Bartels, R, Bauerfeind, U, Beauchamp, M, Beer, D, Beer, R, Belda, F, Bellander, B, Bellier, R, Benali, H, Benard, T, Beqiri, V, Beretta, L, Bernard, F, Bertolini, G, Bilotta, F, Blaabjerg, M, Den Boogert, H, Boutis, K, Bouzat, P, Brooks, B, Brorsson, C, Bullinger, M, Burns, E, Calappi, E, Cameron, P, Carise, E, Castaño león, A, Causin, F, Chevallard, G, Chieregato, A, Christie, B, Cnossen, M, Coles, J, Collett, J, Della Corte, F, Craig, W, Csato, G, Csomos, A, Curry, N, Dahyot fizelier, C, Dawes, H, Dematteo, C, Depreitere, B, Dewey, D, Van Dijck, J, Đilvesi, Đ, Dippel, D, Dizdarevic, K, Donoghue, E, Duek, O, Dulière, G, Dzeko, A, Eapen, G, Emery, C, English, S, Esser, P, Ezer, E, Fabricius, M, Feng, J, Fergusson, D, Figaji, A, Fleming, J, Foks, K, Francony, G, Freedman, S, Freo, U, Frisvold, S, Gagnon, I, Galanaud, D, Gantner, D, Giraud, B, Glocker, B, Golubovic, J, Gómez López, P, Gordon, W, Gradisek, P, Gravel, J, Griesdale, D, Grossi, F, Haagsma, J, Håberg, A, Haitsma, I, Van Hecke, W, Helbok, R, Helseth, E, Van Heugten, C, Hoedemaekers, C, Höfer, S, Horton, L, Hui, J, Huijben, J, Hutchinson, P, Jacobs, B, Van Der Jagt, M, Jankowski, S, Janssens, K, Jelaca, B, Jones, K, Kamnitsas, K, Kaps, R, Karan, M, Katila, A, Kaukonen, K, De Keyser, V, Kivisaari, R, Kolias, A, Kolumbán, B, Kolundžija, K, Kondziella, D, Koskinen, L, Kovács, N, Kramer, A, Kutsogiannis, D, Kyprianou, T, Lagares, A, Lamontagne, F, Latini, R, Lauzier, F, Lazar, I, Ledig, C, Lefering, R, Legrand, V, Levi, L, Lightfoot, R, Lozano, A, Macdonald, S, Major, S, Manara, A, Manhes, P, Maréchal, H, Martino, C, Masala, A, Masson, S, Mattern, J, Mcfadyen, B, Mcmahon, C, Meade, M, Melegh, B, Menovsky, T, Moore, L, Morgado Correia, M, Morganti kossmann, M, Muehlan, H, Mukherjee, P, Murray, L, Van Der Naalt, J, Negru, A, Nelson, D, Nieboer, D, Noirhomme, Q, Nyirádi, J, Oddo, M, Okonkwo, D, Oldenbeuving, A, Ortolano, F, Osmond, M, Payen, J, Perlbarg, V, Persona, P, Pichon, N, Piippo karjalainen, A, Pili floury, S, Pirinen, M, Ple, H, Poca, M, Posti, J, Van Praag, D, Ptito, A, Radoi, A, Ragauskas, A, Raj, R, Real, R, Reed, N, Rhodes, J, Robertson, C, Rocka, S, Røe, C, Røise, O, Roks, G, Rosand, J, Rosenfeld, J, Rosenlund, C, Rosenthal, G, Rossi, S, Rueckert, D, De Ruiter, G, Sacchi, M, Sahakian, B, Sahuquillo, J, Sakowitz, O, Salvato, G, Sánchez porras, R, Sándor, J, Sangha, G, Schäfer, N, Schmidt, S, Schneider, K, Schnyer, D, Schöhl, H, Schoonman, G, Schou, R, Sir, Ö, Skandsen, T, Smeets, D, Sorinola, A, Stamatakis, E, Stevanovic, A, Stevens, R, Sundström, N, Taccone, F, Takala, R, Tanskanen, P, Taylor, M, Telgmann, R, Temkin, N, Teodorani, G, Thomas, M, Tolias, C, Trapani, T, Turgeon, A, Vajkoczy, P, Valadka, A, Valeinis, E, Vallance, S, Vámos, Z, VARGIOLU, ALESSIA, Vega, E, Verheyden, J, Vik, A, Vilcinis, R, Vleggeert lankamp, C, Vogt, L, Volovici, V, Voormolen, D, Vulekovic, P, Vande Vyvere, T, Van Waesberghe, J, Wessels, L, Wildschut, E, Williams, G, Winkler, M, Wolf, S, Wood, G, Xirouchaki, N, Younsi, A, Zaaroor, M, Zelinkova, V, Zemek, R, Zumbo, F, Citerio, G, Vargiolu, A, Zumbo, F., Maas, Andrew I R, Menon, David K, Adelson, P David, Andelic, Nada, Bell, Michael J, Belli, Antonio, Bragge, Peter, Brazinova, Alexandra, Büki, Andrá, Chesnut, Randall M, Citerio, Giuseppe, Coburn, Mark, Cooper, D Jamie, Crowder, A Tamara, Czeiter, Endre, Czosnyka, Marek, Diaz-Arrastia, Ramon, Dreier, Jens P, Duhaime, Ann-Christine, Ercole, Ari, van Essen, Thomas A, Feigin, Valery L, Gao, Guoyi, Giacino, Joseph, Gonzalez-Lara, Laura E, Gruen, Russell L, Gupta, Deepak, Hartings, Jed A, Hill, Sean, Jiang, Ji-yao, Ketharanathan, Naomi, Kompanje, Erwin J O, Lanyon, Linda, Laureys, Steven, Lecky, Fiona, Levin, Harvey, Lingsma, Hester F, Maegele, Marc, Majdan, Marek, Manley, Geoffrey, Marsteller, Jill, Mascia, Luciana, Mcfadyen, Charle, Mondello, Stefania, Newcombe, Virginia, Palotie, Aarno, Parizel, Paul M, Peul, Wilco, Piercy, Jame, Polinder, Suzanne, Puybasset, Loui, Rasmussen, Todd E, Rossaint, Rolf, Smielewski, Peter, Söderberg, Jeannette, Stanworth, Simon J, Stein, Murray B, von Steinbüchel, Nicole, Stewart, William, Steyerberg, Ewout W, Stocchetti, Nino, Synnot, Anneliese, Te Ao, Braden, Tenovuo, Olli, Theadom, Alice, Tibboel, Dick, Videtta, Walter, Wang, Kevin K W, Williams, W Huw, Wilson, Lindsay, Yaffe, Kristine, InTBIR Participants, Investigator, Beretta, Luigi, InTBIR Participants Investigators, Menon, David [0000-0002-3228-9692], Czosnyka, Marek [0000-0003-2446-8006], Ercole, Ari [0000-0001-8350-8093], Newcombe, Virginia [0000-0001-6044-9035], Smielewski, Peter [0000-0001-5096-3938], Apollo - University of Cambridge Repository, Maas A.I.R., Menon D.K., David Adelson P.D., Andelic N., Bell M.J., Belli A., Bragge P., Brazinova A., Buki A., Chesnut R.M., Citerio G., Coburn M., Jamie Cooper D., Tamara Crowder A., Czeiter E., Czosnyka M., Diaz-Arrastia R., Dreier J.P., Duhaime A.-C., Ercole A., van Essen T.A., Feigin V.L., Gao G., Giacino J., Gonzalez-Lara L.E., Gruen R.L., Gupta D., Hartings J.A., Hill S., Jiang J.-Y., Ketharanathan N., Kompanje E.J.O., Lanyon L., Laureys S., Lecky F., Levin H., Lingsma H.F., Maegele M., Majdan M., Manley G., Marsteller J., Mascia L., McFadyen C., Mondello S., Newcombe V., Palotie A., Parizel P.M., Peul W., Piercy J., Polinder S., Puybasset L., Rasmussen T.E., Rossaint R., Smielewski P., Soderberg J., Stanworth S.J., Stein M.B., von Steinbuchel N., Stewart W., Steyerberg E.W., Stocchetti N., Synnot A., Te Ao B., Tenovuo O., Theadom A., Tibboel D., Videtta W., Wang K.K.W., Huw Williams W., Wilson L., Yaffe K., Adams H., Allanson J., Coles J., Hutchinson P.J., Kolias A.G., Sahakian B.J., Stamatakis E., Williams G., Agnoletti V., Martino C., Masala A., Teodorani G., Zumbo F., Amrein K., Ezer E., Kolumban B., Kovacs N., Melegh B., Nyiradi J., Sorinola A., Vamos Z., Andaluz N., Anke A., Frisvold S.K., Antoni A., van As A.B., Figaji A., Audibert G., Azasevac A., Dilvesi D., Golubovic J., Jelaca B., Karan M., Kolundzija K., Negru A., Vulekovic P., Azouvi P., Azzolini M.L., Beretta L., Baciu C., Beqiri V., Chevallard G., Chieregato A., Sacchi M., Badenes R., Belda F.J., Bilotta F., Lozano A., Barlow K.M., Schneider K.J., Bartels R., den Boogert H., Hoedemaekers C., Sir O., Bauerfeind U., Lefering R., Schafer N., Beauchamp M., Gravel J., Beer D., Beer R., Helbok R., Hofer S., Bellander B.-M., Nelson D., Bellier R., Benard T., Carise E., Dahyot-Fizelier C., Giraud B., Benali H., Bernard F., Bertolini G., Masson S., Blaabjerg M., Rosenlund C., Schou R.F., Boutis K., Bouzat P., Francony G., Manhes P., Payen J.-F., Brooks B., Dewey D., Emery C.A., Freedman S., Kramer A., Brorsson C., Koskinen L.-O., Sundstrom N., Bullinger M., Burns E., Calappi E., Ortolano F., Cameron P., Castano-Leon A.M., Gomez Lopez P.A., Lagares A., Causin F., Freo U., Persona P., Rossi S., Christie B., Cnossen M., Dippel D., Foks K., Haagsma J.A., Haitsma I., Huijben J.A., van der Jagt M., Nieboer D., Volovici V., Voormolen D.C., Collett J., Dawes H., Esser P., van Heugten C., Della Corte F., Grossi F., Craig W., Csato G., Csomos A., Curry N., Dematteo C., Meade M., Depreitere B., van Dijck J., de Ruiter G.C.W., Vleggeert-Lankamp C., Dizdarevic K., Donoghue E., Gantner D., Murray L., Trapani T., Vallance S., Duek O., Lazar I., Duliere G.-L., Marechal H., Dzeko A., Eapen G., Jankowski S., English S., Fergusson D., Osmond M., Fabricius M., Kondziella D., Feng J., Hui J., Fleming J., Latini R., Gagnon I., Ptito A., Galanaud D., Glocker B., Kamnitsas K., Ledig C., Rueckert D., Gordon W.A., Gradisek P., Griesdale D., Haberg A.K., van Hecke W., Smeets D., Verheyden J., Vyvere T.V., Helseth E., Roe C., Roise O., Horton L., Jacobs B., van der Naalt J., Janssens K., De Keyser V., Menovsky T., Van Praag D., Jones K.M., Kaps R., Katila A., Posti J., Takala R., Kaukonen K.-M., Kivisaari R., Piippo-Karjalainen A., Raj R., Tanskanen P., Kutsogiannis D., Kyprianou T., Lamontagne F., Lauzier F., Moore L., Turgeon A., Legrand V., Levi L., Zaaroor M., Lightfoot R., Macdonald S., Major S., Vajkoczy P., Wessels L., Winkler M.K.L., Wolf S., Manara A., Thomas M., Mattern J., Sakowitz O., Vogt L., Younsi A., McFadyen B., McMahon C., Correia M.M., Morganti-Kossmann M.C., Rosenfeld J.V., Muehlan H., Schmidt S., Mukherjee P., Noirhomme Q., Oddo M., Okonkwo D.O., Oldenbeuving A.W., Roks G., Schoonman G.G., Perlbarg V., Pichon N., Pili-Floury S., Pirinen M., Ples H., Poca M.A., Radoi A., Sahuquillo J., Ragauskas A., Rocka S., Real R.G.L., Telgmann R., Reed N., Rhodes J., Robertson C., Rosand J., Rosenthal G., Salvato G., Sanchez-Porras R., Sandor J., Sangha G., Schnyer D., Schohl H., Skandsen T., Stevanovic A., van Waesberghe J.V., Stevens R.D., Taccone F.S., Taylor M.S., Zelinkova V., Temkin N., Tolias C.M., Valadka A.B., Valeinis E., Vargiolu A., Vega E., Vik A., Vilcinis R., Wildschut E., Wood G., Xirouchaki N., Zemek R., Maas, A, Menon, D, Adelson, P, Andelic, N, Bell, M, Belli, A, Bragge, P, Brazinova, A, Büki, A, Chesnut, R, Citerio, G, Coburn, M, Cooper, D, Crowder, A, Czeiter, E, Czosnyka, M, Diaz arrastia, R, Dreier, J, Duhaime, A, Ercole, A, Van Essen, T, Feigin, V, Gao, G, Giacino, J, Gonzalez lara, L, Gruen, R, Gupta, D, Hartings, J, Hill, S, Jiang, J, Ketharanathan, N, Kompanje, E, Lanyon, L, Laureys, S, Lecky, F, Levin, H, Lingsma, H, Maegele, M, Majdan, M, Manley, G, Marsteller, J, Mascia, L, Mcfadyen, C, Mondello, S, Newcombe, V, Palotie, A, Parizel, P, Peul, W, Piercy, J, Polinder, S, Puybasset, L, Rasmussen, T, Rossaint, R, Smielewski, P, Söderberg, J, Stanworth, S, Stein, M, Von Steinbüchel, N, Stewart, W, Steyerberg, E, Stocchetti, N, Synnot, A, Te Ao, B, Tenovuo, O, Theadom, A, Tibboel, D, Videtta, W, Wang, K, Williams, W, Wilson, L, Yaffe, K, Adams, H, Agnoletti, V, Allanson, J, Amrein, K, Andaluz, N, Anke, A, Antoni, A, Van As, A, Audibert, G, Azaševac, A, Azouvi, P, Azzolini, M, Baciu, C, Badenes, R, Barlow, K, Bartels, R, Bauerfeind, U, Beauchamp, M, Beer, D, Beer, R, Belda, F, Bellander, B, Bellier, R, Benali, H, Benard, T, Beqiri, V, Beretta, L, Bernard, F, Bertolini, G, Bilotta, F, Blaabjerg, M, Den Boogert, H, Boutis, K, Bouzat, P, Brooks, B, Brorsson, C, Bullinger, M, Burns, E, Calappi, E, Cameron, P, Carise, E, Castaño león, A, Causin, F, Chevallard, G, Chieregato, A, Christie, B, Cnossen, M, Coles, J, Collett, J, Della Corte, F, Craig, W, Csato, G, Csomos, A, Curry, N, Dahyot fizelier, C, Dawes, H, Dematteo, C, Depreitere, B, Dewey, D, Van Dijck, J, Đilvesi, Đ, Dippel, D, Dizdarevic, K, Donoghue, E, Duek, O, Dulière, G, Dzeko, A, Eapen, G, Emery, C, English, S, Esser, P, Ezer, E, Fabricius, M, Feng, J, Fergusson, D, Figaji, A, Fleming, J, Foks, K, Francony, G, Freedman, S, Freo, U, Frisvold, S, Gagnon, I, Galanaud, D, Gantner, D, Giraud, B, Glocker, B, Golubovic, J, Gómez López, P, Gordon, W, Gradisek, P, Gravel, J, Griesdale, D, Grossi, F, Haagsma, J, Håberg, A, Haitsma, I, Van Hecke, W, Helbok, R, Helseth, E, Van Heugten, C, Hoedemaekers, C, Höfer, S, Horton, L, Hui, J, Huijben, J, Hutchinson, P, Jacobs, B, Van Der Jagt, M, Jankowski, S, Janssens, K, Jelaca, B, Jones, K, Kamnitsas, K, Kaps, R, Karan, M, Katila, A, Kaukonen, K, De Keyser, V, Kivisaari, R, Kolias, A, Kolumbán, B, Kolundžija, K, Kondziella, D, Koskinen, L, Kovács, N, Kramer, A, Kutsogiannis, D, Kyprianou, T, Lagares, A, Lamontagne, F, Latini, R, Lauzier, F, Lazar, I, Ledig, C, Lefering, R, Legrand, V, Levi, L, Lightfoot, R, Lozano, A, Macdonald, S, Major, S, Manara, A, Manhes, P, Maréchal, H, Martino, C, Masala, A, Masson, S, Mattern, J, Mcfadyen, B, Mcmahon, C, Meade, M, Melegh, B, Menovsky, T, Moore, L, Morgado Correia, M, Morganti kossmann, M, Muehlan, H, Mukherjee, P, Murray, L, Van Der Naalt, J, Negru, A, Nelson, D, Nieboer, D, Noirhomme, Q, Nyirádi, J, Oddo, M, Okonkwo, D, Oldenbeuving, A, Ortolano, F, Osmond, M, Payen, J, Perlbarg, V, Persona, P, Pichon, N, Piippo karjalainen, A, Pili floury, S, Pirinen, M, Ple, H, Poca, M, Posti, J, Van Praag, D, Ptito, A, Radoi, A, Ragauskas, A, Raj, R, Real, R, Reed, N, Rhodes, J, Robertson, C, Rocka, S, Røe, C, Røise, O, Roks, G, Rosand, J, Rosenfeld, J, Rosenlund, C, Rosenthal, G, Rossi, S, Rueckert, D, De Ruiter, G, Sacchi, M, Sahakian, B, Sahuquillo, J, Sakowitz, O, Salvato, G, Sánchez porras, R, Sándor, J, Sangha, G, Schäfer, N, Schmidt, S, Schneider, K, Schnyer, D, Schöhl, H, Schoonman, G, Schou, R, Sir, Ö, Skandsen, T, Smeets, D, Sorinola, A, Stamatakis, E, Stevanovic, A, Stevens, R, Sundström, N, Taccone, F, Takala, R, Tanskanen, P, Taylor, M, Telgmann, R, Temkin, N, Teodorani, G, Thomas, M, Tolias, C, Trapani, T, Turgeon, A, Vajkoczy, P, Valadka, A, Valeinis, E, Vallance, S, Vámos, Z, Vargiolu, A, Vega, E, Verheyden, J, Vik, A, Vilcinis, R, Vleggeert lankamp, C, Vogt, L, Volovici, V, Voormolen, D, Vulekovic, P, Vande Vyvere, T, Van Waesberghe, J, Wessels, L, Wildschut, E, Williams, G, Winkler, M, Wolf, S, Wood, G, Xirouchaki, N, Younsi, A, Zaaroor, M, Zelinkova, V, Zemek, R, Zumbo, F, Pediatric Surgery, Intensive Care, and Public Health

Subjects
medicine.medical_specialty, EVIDENCE-BASED MEDICINE, Treatment outcome, Poison control, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], EMERGENCY-DEPARTMENT VISITS, Review, PLACEBO-CONTROLLED TRIAL, Middle income country, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], 03 medical and health sciences, 0302 clinical medicine, Intensive care, Brain Injuries, Traumatic, Journal Article, medicine, traumatic barin injury, Humans, 030212 general & internal medicine, Clinical care, Neurologic disease, Psychiatry, DIAGNOSTIC MANAGEMENT STRATEGIES, business.industry, RANDOMIZED CONTROLLED-TRIAL, ACUTE SUBDURAL-HEMATOMA, SEVERE HEAD-INJURY, ROAD TRAFFIC INJURIES, brain injury, Hospital care, 3. Good health, Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10], Brain Injuries, Health care cost, PATIENT-REPORTED OUTCOMES, Human medicine, Neurology (clinical), business, Humanities, 030217 neurology & neurosurgery, GLASGOW COMA SCALE
Abstract

Executive summary A concerted effort to tackle the global health problem posed by traumatic brain injury (TBI) is long overdue. TBI is a public health challenge of vast, but insufficiently recognised, proportions. Worldwide, more than 50 million people have a TBI each year, and it is estimated that about half the world’s population will have one or more TBIs over their lifetime. TBI is the leading cause of mortality in young adults and a major cause of death and disability across all ages in all countries, with a disproportionate burden of disability and death occurring in low-income and middle-income countries (LMICs). It has been estimated that TBI costs the global economy approximately $US400 billion annually. Deficiencies in prevention, care, and research urgently need to be addressed to reduce the huge burden and societal costs of TBI. This Commission highlights priorities and provides expert recommendations for all stakeholders— policy makers, funders, health-care professionals, researchers, and patient representatives—on clinical and research strategies to reduce this growing public health problem and improve the lives of people with TBI. The epidemiology of TBI is changing: in high-income countries, the number of elderly people with TBI is increasing, mainly due to falls, while in LMICs, the burden of TBI from road traffic incidents is increasing. Data on the frequency of TBI and TBI-related deaths and on the economic impact of brain trauma are often incomplete and vary between countries. Improved, accurate epidemiological monitoring and robust healtheconomic data collection are needed to inform healthcare policy and prevention programmes. Highly developed and coordinated systems of care are crucial for management of patients with TBI. However, in practice, implementation of such frameworks varies greatly and disconnects exist in the chain of care. Optimisation of systems of care should be high on the policy agenda and could yield substantial gains in terms of both patient outcomes and costs to society. TBI is a complex condition, and strong evidence to support treatment guidelines and recommendations is scarce. Most multicentre clinical trials of medical and surgical interventions have failed to show efficacy, despite promising preclinical results. At the bedside, treatment strategies are generally based on guidelines that promote a one-size-fits-all approach and are insufficiently targeted to the needs of individual patients. Attempts to individualise treatment are challenging owing to the diversity of TBI, and are hampered by the use of simplistic methods to characterise its initial type and severity. Advances in genomics, blood biomarkers, magnetic resonance imaging (MRI), and pathophysiological monitoring, combined with informatics to integrate data from multiple sources, offer new research avenues to improve disease characterisation and monitoring of disease evolution. These tools can also aid understanding of disease mechanisms and facilitate targeted treatment strategies for individual patients. Individualised management in the postacute phase and evaluation of the effectiveness of treatment and care processes depend on accurate quantification of outcomes. In practice, however, the use of simplistic methods hinders efforts to quantify outcomes after TBI of all severities. Development and validation of multidimensional approaches will be essential to improve measurement of clinical outcomes, for both research and patient care. In particular, we need to find better ways to characterise the currently under-recognised risk of long-term disabling sequelae in patients with relatively mild injuries. Prognostic models are important to help clinicians to provide reliable information to patients and relatives, and to facilitate comparative audit of care between centres and countries. There is an urgent need for further development, validation, and implementation of prognostic models in TBI, particularly for less severe TBI. This multitude of challenges in TBI—encompassing systems of care, clinical management, and research strategy—demands novel approaches to the generation of new evidence and its implementation in clinical practice. Comparative effectiveness research (CER) offers opportunities to capitalise on the diversity of TBI and systems of care and enables assessment of therapies in real-world conditions; high-quality CER studies can provide strong evidence to support guideline recommendations. The global challenges posed by TBI necessitate global collaborations and a change in research culture to endorse broad data sharing. This Commission covers a range of topics that need to be addressed to confront the global burden of TBI and reduce its effects on individuals and society: epidemiology (section 1); health economics (section 2); prevention (section 3); systems of care (section 4); clinical management (section 5); characterisation of TBI (section 6); outcome assessment (section 7); prognosis (section 8); and new directions for acquiring and implementing evidence (section 9). Table 1 summarises key messages from the Commission and provides recommendations to advance clinical care and research in TBI. We must increase awareness of the scale of the challenge posed by TBI. If we are to tackle the individual and societal burden of TBI, these efforts need to go beyond a clinical and research audience and address the public, politicians, and other stakeholders. We need to develop and implement policies for better prevention and systems of care in order to improve outcomes for individuals with TBI. We also need a commitment to substantial long-term investment in TBI research across a range of disciplines to determine best practice and facilitate individualised management strategies. A combination of innovative research methods and global collaboration, and ways to effectively translate progress in basic and clinical research into clinical practice and public health policy, will be vital for progress in the field.

Published
2017

10. Variation in neurosurgical management of traumatic brain injury: a survey in 68 centers participating in the CENTER-TBI study (vol 161, pg 453, 2019)

Author

den Boogert H, Cnossen M, Lingsma H, Peul W, Ackerlund C, Adams H, Agnoletti V, Allanson J, Amrein K, Andaluz N, Andelic N, Andreassen L, Antun A, Anke A, Antoni A, Ardon H, Audibert G, Auslands K, Azouvi P, Azzolini M, Baciu C, Badenes R, Bartels R, Barzo P, Bauerfeind U, Beauvais R, Beer R, Belda F, Bellander B, Belli A, Bellier R, Benali H, Benard T, Berardino M, Beretta L, Beynon C, Bilotta F, Binder H, Biqiri E, Blaabjerg M, Bouzat P, Bragge P, Brazinova A, Brinck V, Brooker J, Brorsson C, Buki A, Bullinger M, Calappi E, Calvi M, Cameron P, Carbayo L, Carbonara M, Carise E, Carpenter K, Castano-Leon A, Causin F, Chevallard G, Chieregato A, Citerio G, Coburn M, Coles J, Coles-Kemp L, Collett J, Cooper J, Correia M, Covic A, Curry N, Czeiter E, Czosnyka M, Dahyot-Fizelier C, Damas F, Damas P, Dawes H, De Keyser V, Francesco D, Depreitere B, de Ruiter G, Dilvesi D, Ding S, Dippel D, Dixit A, Donoghue E, Dreier J, Duliere G, Eapen G, Engemann H, Ercole A, Esser P, Ezer E, Fabricius M, Feigin V, Feng J, Foks K, Fossi F, Francony G, Freo U, Frisvold S, Furmanov A, Gagliardo P, Galanaud D, Gantner D, Gao G, Geleijns K, George P, Ghuysen A, Giga L, Giraud B, Ben Glocker, Golubovic J, Gomez P, Grossi F, Gruen R, Gupta D, Haagsma J, Haitsma I, Hartings J, Helbok R, Helseth E, Hertle D, Hoedemaekers A, Hoefer S, Horton L, Huijben J, Hutchinson P, Haberg A, Jacobs B, Jankowski S, Jarrett M, Jelaca B, Jiang J, Jones K, Kamnitsas K, Karan M, Katila A, Kaukonen M, Kerforne T, Kivisaari R, Kolias A, Kolumban B, Kompanje E, Kolundzija K, Kondziella D, Koskinen L, Kovacs N, Lagares A, Lanyon L, Laureys S, Lecky F, Ledig C, Lefering R, Legrand V, Lei J, Levi L, Lightfoot R, Loeckx D, Lozano A, Maas A, MacDonald S, Maegele M, Majdan M, Major S, Manara A, Manley G, Martin D, Martin L, Martino C, Maruenda A, Marechal H, Masala A, Mattern J, McFadyen C, McMahon C, Melegh B, Menon D, Menovsky T, Morganti-Kossmann C, Mulazzi D, Muraleedharan V, Murray L, Muhlan H, Nair N, Negru A, Nelson D, Newcombe V, Nieboer D, Noirhomme Q, Nyiradi J, Oddo M, Oldenbeuving A, Oresic M, Ortolano F, Palotie A, Parizel P, Patruno A, Payen J, Perera N, Perlbarg V, Persona P, Piippo-Karjalainen A, Pili F, Pirinen M, Ples H, Poca M, Polinder S, Pomposo I, Posti J, Puybasset L, Radoi A, Ragauskas A, Raj R, Rambadagalla M, Real R, Rehorcikova V, Rhodes J, Ripatti S, Rocka S, Roe C, Roise O, Roks G, Rosand J, Rosenfeld J, Rosenlund C, Rosenthal G, Rossaint R, Rossi S, Rueckert D, Rusnak M, Sacchi M, Sahakian B, Sahuquillo J, Sakowitz O, Sala F, Sanchez-Porras R, Sandor J, Santos E, Sasu L, Savo D, Schaffer N, Schipper I, Schlosser B, Schmidt S, Schoechl H, Schoonman G, Schou R, Schwendenwein E, Scholl M, Sir O, Skandsen T, Smakman L, Smeets D, Smielewski P, Sorinola A, Stamatakis E, Stanworth S, Steinbuchel N, Stevanovic A, Stevens R, Stewart W, Steyerberg E, Stocchetti N, Sundstrom N, Synnot A, Taccone F, Takala R, Tamas V, Tanskanen P, Taylor M, Ao B, Tenovuo O, Telgmann R, Teodorani G, Theadom A, Thomas M, Tibboel D, Tolias C, Tshibanda J, Trapani T, Tudora C, Vajkoczy P, Vallance S, Valeinis E, Van der Steen G, van der Jagt M, van der Naalt J, van Dijck J, van Essen T, van Hecke W, van Heugten C, van Praag D, Vyvere T, Van Waesberghe J, Vanhaudenhuyse A, Vargiolu A, Vega E, Velt K, Verheyden J, Vespa P, Vik A, Vilcinis R, Vizzino G, Vleggeert-Lankamp C, Volovici V, Voormolen D, Vulekovic P, Vamos Z, Wade D, Wang K, Wang L, Wessels L, Wildschut E, Williams G, Wilson L, Winkler M, Wolf S, Ylen P, Younsi A, Zaaroor M, Yang Z, Ziverte A, Zumbo F, and CENTER-TBI Investigators

Published
2019

18. Brain death and postmortem organ donation: report of a questionnaire from the CENTER-TBI study

Author

Van Veen E., Van Der Jagt M., Cnossen M. C., Maas A. I. R., De Beaufort I. D., Menon D. K., Citerio G., Stocchetti N., Rietdijk W. J. R., Van Dijck J. T. J. M., Kompanje E. J. O., Ackerlund C., Adams H., Agnoletti V., Allanson J., Amrein K., Andaluz N., Andelic N., Andreassen L., Antun A., Anke A., Antoni A., Ardon H., Audibert G., Auslands K., Azouvi P., Azzolini M. L., Baciu C., Badenes R., Bartels R., Barzo P., Bauerfeind U., Beauvais R., Beer R., Francisco J. B., Bellander B. -M., Belli A., Bellier R., Benali H., Benard T., Berardino M., Beretta L., Beynon C., Bilotta F., Binder H., Biqiri E., Blaabjerg M., Den Boogert H., Bouzat P., Bragge P., Brazinova A., Brinck V., Brooker J., Brorsson C., Buki A., Bullinger M., Calappi E., Calvi M. R., Cameron P., Lozano G. C., Carbonara M., Carise E., Carpenter K., Castano-Leon A. M., Causin F., Chevallard G., Chieregato A., Coburn M., Coles J., Coles-Kemp L., Collett J., Cooper J. D., Correia M., Covic A., Curry N., Czeiter E., Czosnyka M., Dahyot-Fizelier C., Damas F., Damas P., Dawes H., De Keyser V., Della Corte F., Depreitere B., De Ruiter Godard C. W., Dilvesi D., Ding S., Dippel D., Dixit A., Donoghue E., Dreier J., Duliere G. -L., Eapen G., Engemann H., Ercole A., Esser P., Ezer E., Fabricius M., Feigin V. L., Feng J., Foks K., Fossi F., Francony G., Freo U., Frisvold S., Furmanov A., Gagliardo P., Galanaud D., Gantner D., Gao G., Geleijns K., George P., Ghuysen A., Giga L., Giraud B., Glocker B., Golubovic J., Gomez P. A., Grossi F., Gruen R. L., Gupta D., Haagsma J. A., Haitsma I., Hartings J. A., Helbok R., Helseth E., Hertle D., Hoedemaekers A., Hoefer S., Horton L., Huijben J., Hutchinson P. J., Haberg A. K., Jacobs B., Jankowski S., Jarrett M., Jelaca B., Jiang J. -Y., Jones K., Kamnitsas K., Karan M., Katila A., Kaukonen M., Kerforne T., Kivisaari R., Kolias A. G., Kolumban B., Kolundzija K., Kondziella D., Koskinen L. -O., Kovacs N., Lagares A., Lanyon L., Laureys S., Lecky F., Ledig C., Lefering R., Legrand V., Lei J., Levi L., Lightfoot R., Lingsma H., Loeckx D., Lozano A., MacDonald S., Maegele M., Majdan M., Major S., Manara A., Manley G., Didier M., Martin L. F., Martino C., Maruenda A., Marechal H., Masala A., Mattern J., McFadyen C., McMahon C., Melegh B., Menovsky T., Morganti-Kossmann C., Mulazzi D., Muraleedharan V., Murray L., Muhlan H., Nair N., Negru A., Nelson D., Newcombe V., Nieboer D., Noirhomme Q., Nyiradi J., Oddo M., Oldenbeuving A., Oresic M., Ortolano F., Palotie A., Parizel P. M., Patruno A., Payen J. -F., Perera N., Perlbarg V., Persona P., Peul W., Piippo-Karjalainen A., Floury S. P., Pirinen M., Ples H., Poca M. A., Polinder S., Pomposo I., Posti J., Puybasset L., Radoi A., Ragauskas A., Raj R., Rambadagalla M., Real R., Rehorcikova V., Rhodes J., Ripatti S., Rocka S., Roe C., Roise O., Roks G., Rosand J., Rosenfeld J., Rosenlund C., Rosenthal G., Rossaint R., Rossi S., Rueckert D., Rusnak M., Sacchi M., Sahakian B., Sahuquillo J., Sakowitz O., Sala F., Sanchez-Porras R., Sandor J., Santos E., Sasu L., Savo D., Schaffer N., Schipper I., Schlosser B., Schmidt S., Schoechl H., Schoonman G., Schou R. F., Schwendenwein E., Scholl M., Sir O., Skandsen T., Smakman L., Smeets D., Smielewski P., Sorinola A., Stamatakis E., Stanworth S., Steinbuchel N., Stevanovic A., Stevens R., Stewart W., Steyerberg E. W., Sundstrom N., Synnot A., Taccone F. S., Takala R., Tamas V., Tanskanen P., Taylor M. S., Te Ao B., Tenovuo O., Telgmann R., Teodorani G., Theadom A., Thomas M., Tibboel D., Tolias C., Tshibanda J. -F. L., Trapani T., Tudora C. M., Vajkoczy P., Vallance S., Valeinis E., Van Der Steen G., Van Der Naalt J., Van Essen T. A., Van Hecke W., Van Heugten C., Van Praag D., Vyvere T. V., Van Waesberghe J., Vanhaudenhuyse A., Vargiolu A., Vega E., Velt K., Verheyden J., Vespa P. M., Vik A., Vilcinis R., Vizzino G., Vleggeert-Lankamp C., Volovici V., Voormolen D., Vulekovic P., Vamos Z., Wade D., Wang K. K. W., Wang L., Wessels L., Wildschut E., Williams G., Wilson L., Winkler M. K. L., Wolf S., Ylen P., Younsi A., Zaaroor M., Zhihui Y., Ziverte A., Zumbo F., Intensive Care, Public Health, van Veen, Ernest, van der Jagt, Mathieu, Cnossen, Maryse C., Maas, Andrew I R, de Beaufort, Inez D., Menon, David K., Citerio, Giuseppe, Stocchetti, Nino, Rietdijk, Wim J R, van Dijck, Jeroen T J M, Kompanje, Erwin J O (CENTER-TBI investigators and participants), Beretta, Luigi, Apollo - University of Cambridge Repository, Ragauskas, Arminas, Rocka, Saulius, Vilcinis, Rimantas, „Springer' grupė, Neurokirurgian yksikkö, Clinicum, Van Veen E., Van Der Jagt M., Cnossen M.C., Maas A.I.R., De Beaufort I.D., Menon D.K., Citerio G., Stocchetti N., Rietdijk W.J.R., Van Dijck J.T.J.M., Kompanje E.J.O., Ackerlund C., Adams H., Agnoletti V., Allanson J., Amrein K., Andaluz N., Andelic N., Andreassen L., Antun A., Anke A., Antoni A., Ardon H., Audibert G., Auslands K., Azouvi P., Azzolini M.L., Baciu C., Badenes R., Bartels R., Barzo P., Bauerfeind U., Beauvais R., Beer R., Francisco J.B., Bellander B.-M., Belli A., Bellier R., Benali H., Benard T., Berardino M., Beretta L., Beynon C., Bilotta F., Binder H., Biqiri E., Blaabjerg M., Den Boogert H., Bouzat P., Bragge P., Brazinova A., Brinck V., Brooker J., Brorsson C., Buki A., Bullinger M., Calappi E., Calvi M.R., Cameron P., Lozano G.C., Carbonara M., Carise E., Carpenter K., Castano-Leon A.M., Causin F., Chevallard G., Chieregato A., Coburn M., Coles J., Coles-Kemp L., Collett J., Cooper J.D., Correia M., Covic A., Curry N., Czeiter E., Czosnyka M., Dahyot-Fizelier C., Damas F., Damas P., Dawes H., De Keyser V., Della Corte F., Depreitere B., De Ruiter Godard C.W., Dilvesi D., Ding S., Dippel D., Dixit A., Donoghue E., Dreier J., Duliere G.-L., Eapen G., Engemann H., Ercole A., Esser P., Ezer E., Fabricius M., Feigin V.L., Feng J., Foks K., Fossi F., Francony G., Freo U., Frisvold S., Furmanov A., Gagliardo P., Galanaud D., Gantner D., Gao G., Geleijns K., George P., Ghuysen A., Giga L., Giraud B., Glocker B., Golubovic J., Gomez P.A., Grossi F., Gruen R.L., Gupta D., Haagsma J.A., Haitsma I., Hartings J.A., Helbok R., Helseth E., Hertle D., Hoedemaekers A., Hoefer S., Horton L., Huijben J., Hutchinson P.J., Haberg A.K., Jacobs B., Jankowski S., Jarrett M., Jelaca B., Jiang J.-Y., Jones K., Kamnitsas K., Karan M., Katila A., Kaukonen M., Kerforne T., Kivisaari R., Kolias A.G., Kolumban B., Kolundzija K., Kondziella D., Koskinen L.-O., Kovacs N., Lagares A., Lanyon L., Laureys S., Lecky F., Ledig C., Lefering R., Legrand V., Lei J., Levi L., Lightfoot R., Lingsma H., Loeckx D., Lozano A., MacDonald S., Maegele M., Majdan M., Major S., Manara A., Manley G., Didier M., Martin L.F., Martino C., Maruenda A., Marechal H., Masala A., Mattern J., McFadyen C., McMahon C., Melegh B., Menovsky T., Morganti-Kossmann C., Mulazzi D., Muraleedharan V., Murray L., Muhlan H., Nair N., Negru A., Nelson D., Newcombe V., Nieboer D., Noirhomme Q., Nyiradi J., Oddo M., Oldenbeuving A., Oresic M., Ortolano F., Palotie A., Parizel P.M., Patruno A., Payen J.-F., Perera N., Perlbarg V., Persona P., Peul W., Piippo-Karjalainen A., Floury S.P., Pirinen M., Ples H., Poca M.A., Polinder S., Pomposo I., Posti J., Puybasset L., Radoi A., Ragauskas A., Raj R., Rambadagalla M., Real R., Rehorcikova V., Rhodes J., Ripatti S., Rocka S., Roe C., Roise O., Roks G., Rosand J., Rosenfeld J., Rosenlund C., Rosenthal G., Rossaint R., Rossi S., Rueckert D., Rusnak M., Sacchi M., Sahakian B., Sahuquillo J., Sakowitz O., Sala F., Sanchez-Porras R., Sandor J., Santos E., Sasu L., Savo D., Schaffer N., Schipper I., Schlosser B., Schmidt S., Schoechl H., Schoonman G., Schou R.F., Schwendenwein E., Scholl M., Sir O., Skandsen T., Smakman L., Smeets D., Smielewski P., Sorinola A., Stamatakis E., Stanworth S., Steinbuchel N., Stevanovic A., Stevens R., Stewart W., Steyerberg E.W., Sundstrom N., Synnot A., Taccone F.S., Takala R., Tamas V., Tanskanen P., Taylor M.S., Te Ao B., Tenovuo O., Telgmann R., Teodorani G., Theadom A., Thomas M., Tibboel D., Tolias C., Tshibanda J.-F.L., Trapani T., Tudora C.M., Vajkoczy P., Vallance S., Valeinis E., Van Der Steen G., Van Der Naalt J., Van Essen T.A., Van Hecke W., Van Heugten C., Van Praag D., Vyvere T.V., Van Waesberghe J., Vanhaudenhuyse A., Vargiolu A., Vega E., Velt K., Verheyden J., Vespa P.M., Vik A., Vilcinis R., Vizzino G., Vleggeert-Lankamp C., Volovici V., Voormolen D., Vulekovic P., Vamos Z., Wade D., Wang K.K.W., Wang L., Wessels L., Wildschut E., Williams G., Wilson L., Winkler M.K.L., Wolf S., Ylen P., Younsi A., Zaaroor M., Zhihui Y., Ziverte A., Zumbo F., Section Neuropsychology, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, RS: FPN NPPP I, Psychiatrie & Neuropsychologie, Menon, David [0000-0002-3228-9692], Ročka, Saulius, Molecular Neuroscience and Ageing Research (MOLAR), CENTER-TBI Investigators, van Veen, E, van der Jagt, M, Cnossen, M, Maas, A, de Beaufort, I, Menon, D, Citerio, G, Stocchetti, N, Rietdijk, W, van Dijck, J, and Kompanje, E

Subjects
Neurology, Internationality, Traumatic/complications, brain death, ethics, postmortem organ donation, traumatic brain injury, ventricular drainage, withdrawing life-sustaining measures, GUIDELINES, Critical Care and Intensive Care Medicine, 0302 clinical medicine, Traumatic brain injury, Trauma Centers, WORLDWIDE, Surveys and Questionnaires, Brain Injuries, Traumatic, Response rate (survey), Brain death, VDP::Medical disciplines: 700::Clinical medical disciplines: 750, VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750, lcsh:Medical emergencies. Critical care. Intensive care. First aid, Tissue and Organ Procurement/legislation & jurisprudence, POLICIES, Europe, VARIABILITY, Neurosurgery, Clinical evaluation, medicine.medical_specialty, Tissue and Organ Procurement, Withdrawing life-sustaining measure, Other Research Radboud Institute for Molecular Life Sciences [Radboudumc 0], Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], 03 medical and health sciences, Neurological assessment, medicine, Humans, Organ donation, Ethics, Postmortem organ donation, Ventricular drainage, Withdrawing life-sustaining measures, Ethic, business.industry, Research, Brain Injuries, Traumatic/complications, 3112 Neurosciences, 030208 emergency & critical care medicine, ADULTS, lcsh:RC86-88.9, Traumatic brain injury, Brain death, Ethics, Postmortem organ donation, Withdrawing life-sustaining measures, Ventricular drainage, medicine.disease, 3126 Surgery, anesthesiology, intensive care, radiology, Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10], Trauma Centers/organization & administration, Brain Injuries, Emergency medicine, Human medicine, business, 030217 neurology & neurosurgery, Regional differences
Abstract

Source at https://doi.org/10.1186/s13054-018-2241-4. Licensed CC BY-NC-ND 4.0. Background: We aimed to investigate the extent of the agreement on practices around brain death and postmortem organ donation. Methods: Investigators from 67 Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study centers completed several questionnaires (response rate: 99%). Results: Regarding practices around brain death, we found agreement on the clinical evaluation (prerequisites and neurological assessment) for brain death determination (BDD) in 100% of the centers. However, ancillary tests were required for BDD in 64% of the centers. BDD for nondonor patients was deemed mandatory in 18% of the centers before withdrawing life-sustaining measures (LSM). Also, practices around postmortem organ donation varied. Organ donation after circulatory arrest was forbidden in 45% of the centers. When withdrawal of LSM was contemplated, in 67% of centers the patients with a ventricular drain in situ had this removed, either sometimes or all of the time. Conclusions: This study showed both agreement and some regional differences regarding practices around brain death and postmortem organ donation. We hope our results help quantify and understand potential differences, and provide impetus for current dialogs toward further harmonization of practices around brain death and postmortem organ donation.

Published
2018

19. Developing allometric models to predict the individual aboveground biomass of shrubs worldwide.

Author

Conti, G., Gorné, L. D., Zeballos, S. R., Lipoma, M. L., Gatica, G., Kowaljow, E., Whitworth‐Hulse, J. I., Cuchietti, A., Poca, M., Pestoni, S., Fernandes, P. M., and Kerkhoff, Andrew

Subjects
PLANT biomass, BIOMASS estimation, STANDARD deviations, BIOMASS
Abstract

Aim: Existing global models to predict standing biomass are based on trees characterized by a single principal stem, well developed in height. However, their use in open woodlands and shrublands, characterized by multistemmed species with substantial crown development, generates a high level of uncertainty in biomass estimates. This limitation led us to (a) develop global models of shrub individual aboveground biomass based on simple allometric variables, (b) to compare the fit of these models with existing global biomass models, and (c) to assess whether models fit change when bioclimatic variables are considered. Location: Global. Time period: Present. Major taxa studied: 118 species of shrubs. Methods: We compile a database of 3,243 individuals across 49 sites distributed worldwide. Including  stem basal diameter, height and crown diameter as predictor variables, we built potential models and compared their fit using generalized least squares. We used mixed effects models to determine if bioclimatic variables improved the accuracy of biomass models. Results: Although the most important variable in terms of predictive capacity was stem basal diameter, crown diameter significantly improved the models' fit, followed by height. Four models were finally chosen, with the best model combining all these variables in the same equation [R2 = 0.930, root mean square error (RMSE) = 0.476]. Selected models performed as well as established global biomass models. Including the individual bioform significantly improved the models' fit. Main conclusions: Stem basal diameter, crown diameter and height measures could be combined to provide robust aboveground biomass (AGB) estimates of individual shrub species. Our study supplements well‐established models developed for trees, allowing more accurate biomass estimation of multistemmed woody individuals. We further provide tools for a methodological standardization of individual biomass quantification in these species. We expect these results contribute to improve the quality of biomass estimates across ecosystems, but also to generate methodological consensus on field biomass assessments in shrubs. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

26. Exploring Dissolved Organic Carbon Variations in a High Elevation Tropical Peatland Ecosystem: Cerro de la Muerte, Costa Rica

Author

Sánchez-Murillo Ricardo, Gastezzi-Arias Paola, Sánchez-Gutiérrez Rolando, Esquivel-Hernández Germain, Pérez-Salazar Roy, and Poca María

Subjects
tropical high elevation peatlands, dissolved organic carbon, optical properties, carbon storage, climate variability, Environmental technology. Sanitary engineering, TD1-1066
Abstract

Tropical peatlands are distributed mainly in coastal lowlands; however high elevation regions exhibit a large prevalence of small and fragmented peatlands that are mostly understudied. Artificial drainage of peatlands to expand the area of cattle farming, horticulture, and urbanization is increasing carbon losses to the atmosphere and streams worldwide. Here, we present an exploratory characterization of dissolved carbon optical properties in ombrotrophic peat bogs of the Talamanca range of Costa Rica, across an altitudinal gradient (2,400–3,100 m a.s.l.) during the rainy season. Dissolved organic matter (DOM) sources and decomposition processes were evaluated in the light of dissolved organic and inorganic carbon (DOC and DIC), optical properties, and major water chemistry. DOC concentrations ranged from 0.2 up to 47.0 mg/L. DIC concentrations were below 2 mg/L and δ13CDIC values indicated a mixture between soil organic matter, CO2 in soil water, and to a lesser degree DIC derived from bacterial CO2. Absolute fluorescence intensity of humic-like peaks was 6–7 times greater than fresh-like peaks across all sites. Fluorescence peak ratios coupled with the biological and humification indexes point to a greater relative contribution of recalcitrant soil-derived DOM. Excitation/Emission matrices denoted a high prevalence of humic and fulvic acids in the peat bogs, with moderate intensities in soluble microbial by-products-like and aromatic protein regions at three sites. Our data provides a baseline to underpin tropical carbon dynamics across high elevation peatlands.

Published
2022
Full Text
View/download PDF

27. Predictive model of mortality in patients with spontaneous bacterial peritonitis.

Author

Poca, M., Alvarado‐Tapias, E., Concepción, M., Pérez‐Cameo, C., Cañete, N., Gich, I., Romero, C., Casas, M., Román, E., Castells, L., Vargas, V., Carrión, J. A., Guarner, C., and Soriano, G.

Subjects
*PERITONITIS, *ALBUMINURIA, *LEUCOCYTES, *ACUTE kidney failure, *LIVER failure, *THERAPEUTICS
Abstract

Background Hospital mortality in patients with spontaneous bacterial peritonitis ( SBP) is high despite albumin treatment, particularly in those with worse liver and/or renal function. Aim To determine the independent predictive factors of in-hospital mortality and to create and validate a predictive model of mortality in patients with SBP. Methods We analysed all cirrhotic patients with high-risk SBP (serum urea ≥11 mmol/L and/or serum bilirubin ≥68 μmol/L) between 2001 and 2011. We developed a predictive model of in-hospital mortality and validated this in a different cohort. Results We included 118 high-risk SBP episodes treated with antibiotics and albumin. In-hospital mortality was 33/118 (28%). The independent predictive factors of in-hospital mortality at SBP diagnosis were serum urea, blood leucocyte count, Child-Pugh score and mean arterial pressure. A predictive model including these four variables showed a discrimination accuracy ( AUC) of 0.850, 95% CI 0.777-0.922. A cut-off point of 0.245 showed a sensitivity of 0.85 and specificity of 0.75. The in-hospital mortality was 28/49 (57.1%) in patients with a model value ≥0.245, and 5/69 (7.2%) in patients with a model value <0.245 ( P < 0.001). The validation series included 161 patients with an in-hospital mortality of 40/161 (24.8%), 30/77 (39.0%) in patients with a model value ≥0.245, and 10/84 (11.9%) in those with a model value <0.245 ( P < 0.001). Conclusions We developed and validated a predictive model of mortality that includes serum urea, blood leucocyte count, Child-Pugh score and mean arterial pressure in high-risk patients with spontaneous bacterial peritonitis. These findings may help to identify patients who would benefit from additional therapeutic strategies. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

32. Cognitive changes after cerebrospinal fluid shunting in young adults with spina bifida and assumed arrested hydrocephalus.

Author

Mataró, M, Poca, M A, Sahuquillo, J, Cuxart, A, Iborra, J, de la Calzada, M D, and Junqué, C

Abstract

Objectives: To establish whether surgery can improve the neuropsychological functioning of young adult patients with spina bifida and apparent clinically arrested hydrocephalus showing abnormal intracranial pressure.Methods: Twenty three young adults with spina bifida and assumed arrested hydrocephalus (diagnosed as active or compensated by continuous intracranial pressure monitoring) underwent surgery. All patients received neuropsychological examination before surgery and 6 months later. Neuropsychological assessment included tests of verbal and visual memory, visuospatial functions, speed of mental processing, and frontal lobe functions.Results: Shunt placement in this subgroup of patients improves neuropsychological functioning, especially in verbal and visual memory and attention and cognitive flexibility.Conclusions: Young adults with spina bifida and suspected non-functioning shunt or non-shunted ventriculomegaly should be carefully monitored to identify those who could benefit from shunting. [ABSTRACT FROM AUTHOR]

Published
2000

33. We report a patient who presented intrahepatic cholangitis and cholecystitis after SARS‐CoV‐2 infection.

Author

Fajardo, J, Núñez, E, Szafranska, J, Poca, M, Lobo, D, Martín, B, Hernández, D, Roig, C, Huerta, A, Corominas, H, Sánchez‐Cabús, S, and Soriano, G

Subjects
CHOLANGITIS, SARS-CoV-2, CHOLECYSTITIS, INFECTION, DIAGNOSIS, INFLAMMATION
Abstract

We report a patient who presented intrahepatic cholangitis and cholecystitis after SARS-CoV-2 infection A 24-year old woman was hospitalized on June 13 2020 for fever (38 C°), right upper abdominal pain, pruritus, and a skin rash of one week's duration. Analysis showed lymphopenia, alterations in liver function tests and a mild increase in C-reactive protein and IL-6 (Table 1). [Extracted from the article]

Published
2021
Full Text
View/download PDF

34. Receptors to agglutinin from Dolichus biflorus (DBA) at the synaptic basal lamina of rat neuromuscular junction.

Author

Ribera, Joan, Esquerda, Josep, Comella, Joan, Poca, M., and Bellmunt, M.

Abstract

The binding of agglutinin from Dolichus biflorus (DBA) and other lectins ( Concanavalin A, agglutinin from wheat germ and lectin from Bandeiraea simplicifolid) to synaptic and extrasynaptic portions of the basal lamina of muscle fibers, was studied with histochemical methods. In rat muscle, DBA-binding is specifically detected at the basal lamina of neuromuscular junction. However, long-term (6 months) denervated end-plate in adult rat muscle failed to bind DBA. During normal development, synaptic DBA receptors appear later than acetylcholine receptors or acetylcholinesterase at the rat neuromuscular junction. Generalized DBA-binding to motor end-plates is first visualized in 3-day-old rats, but section of sciatic nerve in 1-day-old rats prevents the appearence of synaptic DBA-binding on the leg end-plates. It is suggested, therefore, that the synaptic DBA receptors could be related to the postnatal stabilization of rat neuromuscular synapses. [ABSTRACT FROM AUTHOR]

Published
1987
Full Text
View/download PDF

35. Reactive arthritis with a severe lesion of the cervical spine.

Author

Fox, B, Sahuquillo, J, Poca, M A, Huguet, P, and Lience, E

Abstract

Reactive arthritis, or Reiter's disease, characteristically affects the joints of the lower limbs in an asymmetrical pattern. Usually it does not affect the cervical spine, and atlantoaxial subluxations are the exception. This paper describes the case of an HLA-B27-positive female patient with a sexually acquired reactive arthritis where a non-reducible atlantoaxial subluxation was present. The patient was followed from age 27 to 41. By the age of 38, an anterior decompression of the cervico-medullary junction was performed by a transoral approach; in a second stage, the patient underwent an occipito-cervical posterior fusion. The pathological study revealed a non-specific and chronic inflammatory infiltrate. [ABSTRACT FROM PUBLISHER]

Published
1997
Full Text
View/download PDF

42. Cerebral blood flow II.

Author

Triginer, C., Robles, A., Poca, M., Sahuquillo, J., Monforte, R., Báguena, M., Sánchez-Masa, L., Garnacho, A., Deyne, C., Poelaert, J., Vandekerckhove, T., Colardyn, F., Diaz, R., Torres, C., Ayuso, A., Clavel, M., León, A., Robusté, J., Nolla, M., and Priern, R.

Published
1992
Full Text
View/download PDF

43. Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized Trial

Author

Silvia Vidal, Eva Román, Cristina Gely, Juan C. Nieto, Marta Pozuelo, Maria Poca, Carlos Guarner, Cándido Juárez, Germán Soriano, Chaysavanh Manichanh, Institut Català de la Salut, [Román E] Departament de Gastroenterologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Escola Universitària d'Infermeria EUI-Sant Pau, Barcelona, Spain. Institut de Recerca IIB-Sant Pau, Barcelona, Spain. CIBERehd Instituto de Salud Carlos III, Madrid, Spain. [Nieto JC, Gely C] Institut de Recerca IIB-Sant Pau, Barcelona, Spain. [Vidal S] Institut de Recerca IIB-Sant Pau, Barcelona, Spain. Departament de Immunologia,Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Pozuelo M] Vall d’Hebron Institut de Recerca, Barcelona, Spain. [Poca M] Departament de Gastroenterologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. CIBERehd Instituto de Salud Carlos III, Madrid, Spain. [Manichanh C] Vall d’Hebron Institut de Recerca, Barcelona, Spain. CIBERehd Instituto de Salud Carlos III, Madrid, Spain., and Vall d'Hebron Barcelona Hospital Campus

Subjects
medicine.medical_specialty, Cirrhosis, enfermedades del sistema digestivo::enfermedades hepáticas::cirrosis hepática [ENFERMEDADES], Caigudes (Accidents), Digestive System Diseases::Liver Diseases::Liver Cirrhosis [DISEASES], Gut flora, características del estudio::estudio clínico::ensayo clínico::ensayo clínico controlado::ensayo clínico controlado aleatorizado [CARACTERÍSTICAS DE PUBLICACIONES], Placebo, Study Characteristics::Clinical Study::Clinical Trial::Controlled Clinical Trial::Randomized Controlled Trial [PUBLICATION CHARACTERISTICS], Gastroenterology, law.invention, Probiotic, Physiological Phenomena::Diet, Food, and Nutrition::Food::Dietary Supplements::Probiotics [PHENOMENA AND PROCESSES], law, Internal medicine, Other subheadings::Other subheadings::/diet therapy [Other subheadings], Medicine, Otros calificadores::Otros calificadores::/dietoterapia [Otros calificadores], Hepatic encephalopathy, Intestinal permeability, Cirrosi hepàtica - Tractament, Hepatology, biology, business.industry, Environment and Public Health::Public Health::Accidents::Accidental Falls [HEALTH CARE], C-reactive protein, ambiente y salud pública::salud pública::accidentes::caídas accidentales [ATENCIÓN DE SALUD], Zonulin, Original Articles, medicine.disease, biology.organism_classification, Probiòtics, biology.protein, Original Article, business, fenómenos fisiológicos::dieta, alimentación y nutrición::alimentos::suplementos dietéticos::probióticos [FENÓMENOS Y PROCESOS], Assaigs clínics
Abstract

Cirrhosis; Probiotic; Cognitive function Cirrosis; Probiòtic; Funció cognitiva Cirrosis; Probiótico; Función cognitiva Probiotics can modulate gut microbiota, intestinal permeability, and immune response and could therefore improve cognitive dysfunction and help avoid potential consequences, such as falls, in patients with cirrhosis. The aim of this study was to evaluate the effect of a multistrain probiotic on cognitive function, risk of falls, and inflammatory response in patients with cirrhosis. Consecutive outpatients with cirrhosis and cognitive dysfunction (defined by a Psychometric Hepatic Encephalopathy Score [PHES] < -4) and/or falls in the previous year were randomized to receive either a sachet of a high-concentration multistrain probiotic containing 450 billion bacteria twice daily for 12 weeks or placebo. We evaluated the changes in cognitive function (PHES); risk of falls (Timed Up and Go [TUG] test, gait speed, and incidence of falls); systemic inflammatory response; neutrophil oxidative burst; intestinal barrier integrity (serum fatty acid-binding protein 6 [FABP-6] and 2 [FABP-2] and zonulin and urinary claudin-3); bacterial translocation (lipopolysaccharide-binding protein [LBP]); and fecal microbiota. Thirty-six patients were included. Patients treated with the probiotic (n = 18) showed an improvement in the PHES (P = 0.006), TUG time (P = 0.015) and gait speed (P = 0.02), and a trend toward a lower incidence of falls during follow-up (0% compared with 22.2% in the placebo group [n = 18]; P = 0.10). In the probiotic group, we observed a decrease in C-reactive protein (P = 0.01), tumor necrosis factor alpha (P = 0.01), FABP-6 (P = 0.009), and claudin-3 (P = 0.002), and an increase in poststimulation neutrophil oxidative burst (P = 0.002). Conclusion: The multistrain probiotic improved cognitive function, risk of falls, and inflammatory response in patients with cirrhosis and cognitive dysfunction and/or previous falls.

Published
2019

44. TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma

Author

Anido, Judit, Sáez-Borderías, Andrea, Gonzàlez-Juncà, Alba, Rodón, Laura, Folch, Gerard, Carmona, Maria A., Prieto-Sánchez, Rosa M., Barba, Ignasi, Martínez-Sáez, Elena, Prudkin, Ludmila, Cuartas, Isabel, Raventós, Carolina, Martínez-Ricarte, Francisco, Poca, M. Antonia, García-Dorado, David, Lahn, Michael M., Yingling, Jonathan M., Rodón, Jordi, Sahuquillo, Juan, and Baselga, José

Subjects
*GENE targeting, *TRANSFORMING growth factors-beta, *CELL receptors, *CELL populations, *GLIOMAS, *STEM cells, *CANCER relapse, *DNA-binding proteins
Abstract

Summary: Glioma-initiating cells (GICs), also called glioma stem cells, are responsible for tumor initiation, relapse, and therapeutic resistance. Here, we show that TGF-β inhibitors, currently under clinical development, target the GIC compartment in human glioblastoma (GBM) patients. Using patient-derived specimens, we have determined the gene responses to TGF-β inhibition, which include inhibitors of DNA-binding protein (Id)-1 and -3 transcription factors. We have identified a cell population enriched for GICs that expresses high levels of CD44 and Id1 and tend to be located in a perivascular niche. The inhibition of the TGF-β pathway decreases the CD44high/Id1high GIC population through the repression of Id1 and Id3 levels, therefore inhibiting the capacity of cells to initiate tumors. High CD44 and Id1 levels confer poor prognosis in GBM patients. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

46. P937 EARLY TREATMENT WITH TERLIPRESSIN AND ALBUMIN IS EFFECTIVE FOR TYPE-1 HEPATORENAL SYNDROME ASSOCIATED WITH SEPSIS.

Author

Rodriguez, E., Elia, C., Sola, E., Barreto, R., Graupera, I., Andrealli, A., Pereira, G.H., Ariza, X., Poca, M., Sanchez, J., Guevara, M., Soriano, G., Alessandria, C., Fernandez, J., Arroyo, V., and Gines, P.

Subjects
*HEPATORENAL syndrome, *EARLY medical intervention, *ALBUMINS, *SEPSIS, *PHARMACODYNAMICS, *CLINICAL trials, *THERAPEUTICS
Published
2014
Full Text
View/download PDF

48. Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized-trial.

Author

Alvarado-Tapias E, Brujats A, Puente A, Ardevol A, Rodriguez-Arias A, Fajardo J, Pavel O, Garcia-Guix M, Aracil C, Poca M, Cuyàs B, Cantó E, Montañés R, Garcia-Osuna A, Escorsell À, Torras X, and Villanueva C

Abstract

Background Aims: Carvedilol is a non-selective β-blocker (NSBBs) with anti-α1-adrenergic activity, more effective than traditional NSBBs in reducing portal-pressure (HVPG). However, 35%-45% of patients still have insufficient HVPG-decrease. Statins ameliorate endothelial dysfunction, reduce hepatic vascular resistance, and have pleiotropic effects. We investigated whether the addition of simvastatin improves the efficacy of carvedilol on HVPG in cirrhosis with severe portal-hypertension and suboptimal response to traditional-NSBBs., Methods: Patients with cirrhosis and high-risk varices referred for primary prophylaxis were consecutively included. HVPG was measured at baseline and again after i.v.propranolol. Suboptimal responders (HVPG-decrease <20%) were treated with carvedilol and were randomized to double-blind administration of placebo or simvastatin. Chronic HVPG response was assessed after 4-6-weeks, repeating HVPG-measurements after a standard liquid meal to estimate endothelial dysfunction. Plasma samples were obtained before each study to investigate inflammatory parameters., Results: Of 184 eligible patients, 82 were randomized to carvedilol+simvastatin (N=41) or carvedilol+placebo (N=41). Baseline characteristics were similar. HVPG significantly decreased with both, carvedilol+simvastatin (18.6±4-to-15.7±4 mm Hg, p<0.001) and carvedilol+placebo (18.9±3-to-16.9±3 mm Hg, p<0.001). The decrease was greater with carvedilol+simvastatin (2.97±2.5 vs. 2.05±1.6 mm Hg, p=0.031). An HVPG-decrease ≥20% occurred in 37% versus 15% patients respectively (OR:3.37, 95% CI=1.15-9.85; p=0.021). With test-meal, HVPG increased in both groups (p<0.01), although carvedilol+simvastatin attenuated such increment (12±8% vs. 23±16%, p<0.001). Cytokine levels (IL-6,MCP-1,MDA) decreased significantly more with carvedilol+simvastatin (p<0.01). Incidence of adverse events was similar., Conclusion: In patients with severe portal hypertension (all with high-risk varices) and suboptimal hemodynamic response to traditional NSBBs, combined therapy with carvedilol plus simvastatin significantly enhances the portal-pressure reduction achieved with carvedilol-monotherapy, improves endothelial dysfunction and reduces pro-inflammatory cytokines., (Copyright © 2024 American Association for the Study of Liver Diseases.)

Published
2024
Full Text
View/download PDF

49. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study.

Author

Dunn W, Li Y, Singal AK, Simonetto DA, Díaz LA, Idalsoaga F, Ayares G, Arnold J, Ayala-Valverde M, Perez D, Gomez J, Escarate R, Fuentes-López E, Ramirez-Cadiz C, Morales-Arraez D, Zhang W, Qian S, Ahn JC, Buryska S, Mehta H, Dunn N, Waleed M, Stefanescu H, Bumbu A, Horhat A, Attar B, Agrawal R, Cabezas J, Echavaría V, Cuyàs B, Poca M, Soriano G, Sarin SK, Maiwall R, Jalal PK, Higuera-de-la-Tijera F, Kulkarni AV, Rao PN, Guerra-Salazar P, Skladaný L, Kubánek N, Prado V, Clemente-Sanchez A, Rincon D, Haider T, Chacko KR, Romero GA, Pollarsky FD, Restrepo JC, Toro LG, Yaquich P, Mendizabal M, Garrido ML, Marciano S, Dirchwolf M, Vargas V, Jiménez C, Hudson D, García-Tsao G, Ortiz G, Abraldes JG, Kamath PS, Arrese M, Shah VH, Bataller R, and Arab JP

Subjects
Humans, Male, Female, Middle Aged, Retrospective Studies, Adult, Prognosis, Cohort Studies, Aged, Artificial Intelligence, Hepatitis, Alcoholic mortality, Hepatitis, Alcoholic drug therapy
Abstract

Background and Aims: Alcohol-associated hepatitis (AH) poses significant short-term mortality. Existing prognostic models lack precision for 90-day mortality. Utilizing artificial intelligence in a global cohort, we sought to derive and validate an enhanced prognostic model., Approach and Results: The Global AlcHep initiative, a retrospective study across 23 centers in 12 countries, enrolled patients with AH per National Institute for Alcohol Abuse and Alcoholism criteria. Centers were partitioned into derivation (11 centers, 860 patients) and validation cohorts (12 centers, 859 patients). Focusing on 30 and 90-day postadmission mortality, 3 artificial intelligence algorithms (Random Forest, Gradient Boosting Machines, and eXtreme Gradient Boosting) informed an ensemble model, subsequently refined through Bayesian updating, integrating the derivation cohort's average 90-day mortality with each center's approximate mortality rate to produce posttest probabilities. The ALCoholic Hepatitis Artificial INtelligence Ensemble score integrated age, gender, cirrhosis, and 9 laboratory values, with center-specific mortality rates. Mortality was 18.7% (30 d) and 27.9% (90 d) in the derivation cohort versus 21.7% and 32.5% in the validation cohort. Validation cohort 30 and 90-day AUCs were 0.811 (0.779-0.844) and 0.799 (0.769-0.830), significantly surpassing legacy models like Maddrey's Discriminant Function, Model for End-Stage Liver Disease variations, age-serum bilirubin-international normalized ratio-serum Creatinine score, Glasgow, and modified Glasgow Scores ( p < 0.001). ALCoholic Hepatitis Artificial INtelligence Ensemble score also showcased superior calibration against MELD and its variants. Steroid use improved 30-day survival for those with an ALCoholic Hepatitis Artificial INtelligence Ensemble score > 0.20 in both derivation and validation cohorts., Conclusions: Harnessing artificial intelligence within a global consortium, we pioneered a scoring system excelling over traditional models for 30 and 90-day AH mortality predictions. Beneficial for clinical trials, steroid therapy, and transplant indications, it's accessible at: https://aihepatology.shinyapps.io/ALCHAIN/ ., (Copyright © 2024 American Association for the Study of Liver Diseases.)

Published
2024
Full Text
View/download PDF

50. Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes.

Author

Garcia-Guix M, Ardevol A, Sapena V, Alvarado-Tápias E, Huertas A, Brujats A, Fajardo J, Cuyas B, Poca M, Guarner C, Torras X, Escorsell À, and Villanueva C

Subjects
Humans, Female, Male, Middle Aged, Aged, Prognosis, Adrenergic beta-Antagonists therapeutic use, ROC Curve, Hypertension, Portal physiopathology, Hypertension, Portal mortality, Hypertension, Portal etiology, Liver Cirrhosis complications, Liver Cirrhosis mortality, Liver Cirrhosis physiopathology, Ascites physiopathology, Ascites mortality, Ascites etiology, Gastrointestinal Hemorrhage mortality, Gastrointestinal Hemorrhage etiology, Gastrointestinal Hemorrhage physiopathology, Esophageal and Gastric Varices mortality, Esophageal and Gastric Varices physiopathology, Esophageal and Gastric Varices etiology, Portal Pressure
Abstract

Background and Aims: Decompensated-cirrhosis encompasses several stages with different prognosis, such as bleeding, ascites and bleeding-plus-ascites. Development of further-decompensation worsens survival, while non-selective β-blockers (NSBBs) can modify the risk. However, how this applies to each stage is uncertain. We aimed to investigate, in each stage of decompensated-cirrhosis, the influence of further-decompensation on mortality and whether changes in portal-pressure (HVPG) under NSBBs influence these outcomes., Methods: Patients with variceal bleeding were consecutively included differentiating those with bleeding-alone from those who also had ascites. Patients with ascites and high-risk varices referred for primary-prophylaxis were also investigated. A baseline haemodynamic study was performed and was repeated after 1-3-months under NSBBs. Outcomes were investigated by competing-risk., Results: Totally 103 patients had bleeding-alone, 186 bleeding-plus-ascites and 187 ascites-alone. Mean follow-up was 32-months (IQR, 12-60). Patients with bleeding-plus-ascites had higher HVPG and were more hyperdynamic than patients with ascites-alone and these than those with bleeding-alone. At each stage, the mortality risk was more than twice in patients developing further-decompensation vs. those without (p < .001). In each stage, HVPG-decrease under NSBBs showed better discrimination to predict further-decompensation than the baseline MELD, Child-Pugh or HVPG, by time-dependent ROC-curves (c-statistic >70%). At each stage, patients without HVPG-decreases, either ≥10% or ≥20% from the baseline, had higher risk of further-decompensation (sHR from 2.43 to 6.73, p < .01) and worse survival., Conclusions: In each stage of decompensated cirrhosis, mortality risk significantly and very markedly increase with further-decompensation. HVPG-non-response to NSBBs may adequately stratify the risk of further decompensation and death, in each stage. This suggests potential benefit with pre-emptive therapies in HVPG-non-responders at each-stage., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results